

Michael N Pollak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8639656/michael-n-pollak-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

477
papers

40,963
citations

94
h-index

188
g-index

497
ext. papers

45,039
ext. citations

7.3
avg, IF

7.63
L-index

#	Paper	IF	Citations
477	Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.. <i>JNCI Cancer Spectrum</i> , 2022 , 6, pkab091	4.6	0
476	Metformin-induced reductions in tumor growth involves modulation of the gut microbiome.. <i>Molecular Metabolism</i> , 2022 , 101498	8.8	0
475	Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. <i>Cancer Prevention Research</i> , 2021 , 14, 541-550	3.2	4
474	Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study. <i>Frontiers in Oncology</i> , 2021 , 11, 626058	5.3	2
473	Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. <i>Neoplasia</i> , 2021 , 23, 391-399	3.9	3
472	Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3591-3591	2.2	1
471	Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 567-567	2.2	
470	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. <i>Nature Communications</i> , 2021 , 12, 3299	17.4	5
469	The role of GSK3 in metabolic pathway perturbations in cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021 , 1868, 119059	4.9	3
468	Blood biomarkers reflect the effects of obesity and inflammation on the human breast transcriptome. <i>Carcinogenesis</i> , 2021 , 42, 1281-1292	4.6	0
467	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa074	4.6	2
466	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. <i>Nature Medicine</i> , 2021 , 27, 659-667	50.5	52
465	Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. <i>Npj Breast Cancer</i> , 2021 , 7, 18	7.8	1
464	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab070	4.6	
463	A hydride transfer complex reprograms NAD metabolism and bypasses senescence. <i>Molecular Cell</i> , 2021 , 81, 3848-3865.e19	17.6	6
462	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.. <i>Journal of Cancer Prevention</i> , 2021 , 26, 309-317	3	
461	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 999-1008	4	7

460	Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review. <i>BMC Endocrine Disorders</i> , 2020 , 20, 83	3.3	2
459	Repression of LKB1 by Sensitizes -Dependent Lymphoma to Biguanide Treatment. <i>Cell Reports Medicine</i> , 2020 , 1, 100014	18	8
458	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz096	4.6	8
457	A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index. <i>Cancer Prevention Research</i> , 2020 , 13, 203-212	3.2	10
456	Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2266-2273	3.8	1
455	Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. <i>British Journal of Cancer</i> , 2020 , 122, 258-265	8.7	13
454	Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa063	4.6	0
453	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2020 , 13, 1055-1062	3.2	7
452	Cancer Immunoprevention: A Case Report Raising the Possibility of "Immuno-interception". <i>Cancer Prevention Research</i> , 2020 , 13, 351-356	3.2	5
451	Prospective Association of Energy Balance Scores Based on Metabolic Biomarkers with Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 974-981	4	
450	Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. <i>Clinical Cancer Research</i> , 2019 , 25, 7229-7242	12.9	15
449	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 970-982	9.7	25
448	Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e323-e328	3.3	13
447	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019 , 145, 3244-3256	7.5	9
446	Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. <i>Journal of Molecular Endocrinology</i> , 2019 , 62, R83-R103	4.5	6
445	Relationship of circulating insulin-like growth factor-I and binding proteins 1-7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. <i>Breast Cancer Research</i> , 2019 , 21, 81	8.3	3
444	High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. <i>Gastroenterology</i> , 2019 , 157, 492-506.e2	13.3	58
443	Plasma Biomarkers of Insulin and the Insulin-like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz056	4.6	0

442	elF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2019 , 10, 5151	17.4	38
441	mTOR as a central regulator of lifespan and aging. <i>F1000Research</i> , 2019 , 8,	3.6	106
440	Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. <i>BMC Cancer</i> , 2019 , 19, 1133	4.8	9
439	Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. <i>International Journal of Cancer</i> , 2018 , 143, 496-507	7.5	2
438	Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. <i>Aging Cell</i> , 2018 , 17, e12723	9.9	72
437	Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. <i>Epidemiology</i> , 2018 , 29, 246-253	3.1	12
436	Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 953-959	6.4	13
435	Interplay between ShcA Signaling and PGC-1 β Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. <i>Cancer Research</i> , 2018 , 78, 4826-4838	10.1	8
434	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018 , 39, 1431-1437	4.6	26
433	Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. <i>Journal of Proteome Research</i> , 2018 , 17, 3039-3049	5.6	4
432	Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. <i>Journal of Biological Chemistry</i> , 2018 , 293, 12502-12515	5.4	7
431	Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. <i>Cell Metabolism</i> , 2018 , 28, 679-688.e4	24.6	55
430	Translational and HIF-1 β Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. <i>Cell Metabolism</i> , 2018 , 28, 817-832.e8	24.6	42
429	A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. <i>GeroScience</i> , 2018 , 40, 419-436	8.9	111
428	Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. <i>Cell Reports</i> , 2018 , 24, 47-55	10.6	33
427	A phenotype of IGFBP-3 knockout mice revealed by dextran sulfate-induced colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 146-153	4	4
426	Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 914-922	4	6
425	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. <i>Cancer Prevention Research</i> , 2017 , 10, 235-243	3.2	85

424	Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 268	19.4	3
423	Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. <i>Cancer Causes and Control</i> , 2017 , 28, 801-807	2.8	17
422	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1692-1701	5.6	52
421	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. <i>Obesity</i> , 2017 , 25, 1317-1320	8	12
420	Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. <i>Cancer Causes and Control</i> , 2017 , 28, 1441-1452	2.8	10
419	The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4541-4547	5.6	6
418	Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3647-3653	2.2	31
417	Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. <i>British Journal of Cancer</i> , 2017 , 117, 1241-1245	8.7	7
416	The effects of metformin on gut microbiota and the immune system as research frontiers. <i>Diabetologia</i> , 2017 , 60, 1662-1667	10.3	58
415	Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3212-3219	3.1	7
414	Periprostatic adipose inflammation is associated with high-grade prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017 , 20, 418-423	6.2	41
413	Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 267-278	5.6	9
412	Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 85-99	19.4	125
411	Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. <i>Journal of the Endocrine Society</i> , 2017 , 1, 625-637	0.4	40
410	Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. <i>Nutrients</i> , 2017 , 9,	6.7	13
409	Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. <i>Journal of Clinical Investigation</i> , 2017 , 127, 132-136	15.9	26
408	Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10059-10059	2.2	1
407	Metformin to treat prostate cancer (PCa) and prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Results of a randomized double-blind placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced PCa.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16502-e16502	2.2	1

406	Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017 , 8, 50542-50556	3.3	18
405	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. <i>Oncotarget</i> , 2017 , 8, 25928-25941	3.3	12
404	Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 63-63	2.2	
403	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. <i>Cancer Research</i> , 2016 , 76, 7160-7167	10.1	32
402	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. <i>BMJ, The</i> , 2016 , 355, i5340	5.9	9
401	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. <i>Breast Cancer Research</i> , 2016 , 18, 1	8.3	55
400	Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. <i>Breast Cancer Research</i> , 2016 , 18, 24	8.3	15
399	nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. <i>Genome Research</i> , 2016 , 26, 636-48	9.7	129
398	Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. <i>Cancer Research</i> , 2016 , 76, 1935-41	10.1	23
397	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016 , 76, 2288-2300	10.1	85
396	High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ~240-Fold Higher Drug Concentration in Urine than Serum. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 430-8	6.1	12
395	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2283-9	12.9	124
394	Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	26
393	Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL [MCRPC]): A Movember funded multicenter, randomized, controlled phase III study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS5092-TPS5092	2.2	8
392	IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. <i>PLoS ONE</i> , 2016 , 11, e0161158	3.7	31
391	Pioglitazone and the risk of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16574-e16574	2.2	
390	Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. <i>PLoS ONE</i> , 2016 , 11, e0167832	3.7	6
389	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). <i>Oncotarget</i> , 2016 , 7, 65643-65659	3.3	25

388	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1281-8	4	14
387	Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. <i>European Urology</i> , 2016 , 70, 808-815	10.2	24
386	Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. <i>Growth Hormone and IGF Research</i> , 2016 , 26, 11-6	2	5
385	Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?. <i>Cell Metabolism</i> , 2016 , 23, 569-70.6	10.6	103
384	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 101-8	4.4	
383	Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. <i>Aging Cell</i> , 2016 , 15, 811-24	9.9	71
382	Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. <i>American Journal of Epidemiology</i> , 2015 , 182, 187-97	3.8	37
381	5 α -Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2015 , 1, 314-20	13.4	25
380	A prospective study of insulin-like growth factor 1, its binding protein 3, and risk of endometriosis. <i>American Journal of Epidemiology</i> , 2015 , 182, 148-56	3.8	12
379	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 839-47	21.7	251
378	Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 353-60	4.4	3
377	Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. <i>International Journal of Cancer</i> , 2015 , 136, 2418-26	7.5	57
376	Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations. <i>Biomarkers in Cancer</i> , 2015 , 7, 13-7	7	0
375	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. <i>Journal of Cancer Epidemiology</i> , 2015 , 2015, 203284	2.8	3
374	The use of aspirin and the risk of mortality in patients with prostate cancer. <i>Journal of Urology</i> , 2015 , 193, 1220-5	2.5	19
373	Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 577-85	4.4	12
372	mTOR coordinates protein synthesis, mitochondrial activity and proliferation. <i>Cell Cycle</i> , 2015 , 14, 473-80.7	10.7	261
371	Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. <i>Diabetes</i> , 2015 , 64, 1632-42	0.9	63

370	Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. <i>Breast Cancer Research</i> , 2014 , 16, R8	8.3	27
369	Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). <i>Cancer Causes and Control</i> , 2014 , 25, 385-94	2.8	10
368	Type 2 diabetes and the risk of mortality among patients with prostate cancer. <i>Cancer Causes and Control</i> , 2014 , 25, 329-38	2.8	42
367	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. <i>Molecular and Cellular Endocrinology</i> , 2014 , 384, 117-25	4.4	10
366	Somatic point mutations occurring early in development: a monozygotic twin study. <i>Journal of Medical Genetics</i> , 2014 , 51, 28-34	5.8	57
365	Serine deprivation enhances antineoplastic activity of biguanides. <i>Cancer Research</i> , 2014 , 74, 7521-33	10.1	82
364	Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. <i>Biochemical Journal</i> , 2014 , 462, 475-87	3.8	407
363	Metformin: from mechanisms of action to therapies. <i>Cell Metabolism</i> , 2014 , 20, 953-66	24.6	715
362	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 134, 607-14	4.9	80
361	Quantification of binding of IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 mice. <i>Endocrinology</i> , 2014 , 155, 703-15	4.8	15
360	Metformin directly acts on mitochondria to alter cellular bioenergetics. <i>Cancer & Metabolism</i> , 2014 , 2, 12	5.4	268
359	Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. <i>Nature Medicine</i> , 2014 , 20, 1193-1198	50.5	383
358	Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. <i>European Journal of Cancer</i> , 2014 , 50, 2838-45	7.5	26
357	Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. <i>Cancer Causes and Control</i> , 2014 , 25, 625-32	2.8	22
356	Serum transforming growth factor- β and risk of pancreatic cancer in three prospective cohort studies. <i>Cancer Causes and Control</i> , 2014 , 25, 1083-91	2.8	9
355	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. <i>Nature Medicine</i> , 2014 , 20, 591-3	50.5	77
354	Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). <i>European Urology</i> , 2014 , 66, 468-74	10.2	76
353	Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. <i>Growth Hormone and IGF Research</i> , 2014 , 24, 142-9	2	2

352	Competing risks of death in younger and older postmenopausal breast cancer patients. <i>World Journal of Clinical Oncology</i> , 2014 , 5, 1088-96	2.5	10
351	Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 399-409	6.1	69
350	Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju085	9.7	31
349	The use of metformin in patients with prostate cancer and the risk of death. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2111-8	4	33
348	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 81-90	4.4	58
347	Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. <i>Cancer Causes and Control</i> , 2014 , 25, 1427-37	2.8	5
346	Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	14
345	Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 1925-34	12.9	29
344	Risk of breast cancer by individual insulin use: an international multicenter study. <i>Diabetes Care</i> , 2014 , 37, 134-43	14.6	15
343	Metformin improves healthspan and lifespan in mice. <i>Nature Communications</i> , 2013 , 4, 2192	17.4	822
342	mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. <i>Cell Metabolism</i> , 2013 , 18, 698-711	24.6	482
341	Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1984-93	4	37
340	Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. <i>Cancer Research</i> , 2013 , 73, 4429-38	10.1	151
339	Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts. <i>Prostate</i> , 2013 , 73, 1223-32	4.2	6
338	The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 124-9	14.6	66
337	Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. <i>Carcinogenesis</i> , 2013 , 34, 109-12	4.6	35
336	Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. <i>Journal of Nutrition</i> , 2013 , 143, 189-96	4.1	64
335	Racial variation in vitamin D cord blood concentration in white and black male neonates. <i>Cancer Causes and Control</i> , 2013 , 24, 91-8	2.8	16

334	Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1786-96	4	26
333	Targeting oxidative phosphorylation: why, when, and how. <i>Cancer Cell</i> , 2013 , 23, 263-4	24.3	42
332	Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF- κ B activation. <i>Aging Cell</i> , 2013 , 12, 489-98	9.9	289
331	IGF2 increases de novo steroidogenesis in prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013 , 20, 173-86	3.6	36
330	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. <i>Cell</i> , 2013 , 153, 1064-79	56.2	276
329	Serum leptin and adiponectin levels and risk of renal cell carcinoma. <i>Obesity</i> , 2013 , 21, 1478-85	8	50
328	Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. <i>Cancer Causes and Control</i> , 2013 , 24, 839-45	2.8	0
327	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. <i>Genes and Cancer</i> , 2013 , 4, 535-45	2.9	3
326	Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1881-90	9.7	68
325	Hyperglycemia, insulin resistance, impaired pancreatic β cell function, and risk of pancreatic cancer. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1027-35	9.7	108
324	Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 855-61	4	20
323	Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. <i>Endocrine-Related Cancer</i> , 2013 , 20, 151-60	5.7	39
322	Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. <i>Cancer Prevention Research</i> , 2013 , 6, 91-9	3.2	24
321	The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1877-83	4	49
320	A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 95-103	9.7	78
319	Systemic cancer therapy: achievements and challenges that lie ahead. <i>Frontiers in Pharmacology</i> , 2013 , 4, 57	5.6	125
318	Potential applications for biguanides in oncology. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3693-700	15.9	149
317	Aspirin use in prostate cancer and the risk of death and metastasis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1518-1518	2.2	1

316	Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. <i>PLoS ONE</i> , 2013 , 8, e79710	3.7	26
315	Individual insulin use and the risk of breast cancer: An international clinical epidemiology study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1578-1578	2.2	
314	Metformin and biomarkers relevant to neoplasia in nondiabetic patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14615-e14615	2.2	0
313	Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5070-5070	2.2	
312	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 131-42	4.4	91
311	Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. <i>Cancer Causes and Control</i> , 2012 , 23, 445-54	2.8	9
310	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. <i>Blood</i> , 2012 , 120, 4929-37	2.2	37
309	A prospective study of circulating adipokine levels and risk of multiple myeloma. <i>Blood</i> , 2012 , 120, 4418-20		47
308	Carbon source and myc expression influence the antiproliferative actions of metformin. <i>Cancer Research</i> , 2012 , 72, 6257-67	10.1	36
307	Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II. <i>Breast Cancer Research</i> , 2012 , 14, R44	8.3	13
306	Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 805-12	4.4	26
305	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. <i>Cancer Causes and Control</i> , 2012 , 23, 779-84	2.8	16
304	IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. <i>Experimental Hematology</i> , 2012 , 40, 715-723.e6	3.1	18
303	Investigating metformin for cancer prevention and treatment: the end of the beginning. <i>Cancer Discovery</i> , 2012 , 2, 778-90	24.4	392
302	Metformin reduces endogenous reactive oxygen species and associated DNA damage. <i>Cancer Prevention Research</i> , 2012 , 5, 536-43	3.2	224
301	Insulin-like growth factor axis and risk of type 2 diabetes in women. <i>Diabetes</i> , 2012 , 61, 2248-54	0.9	98
300	IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. <i>Science Signaling</i> , 2012 , 5, ra92	8.8	95
299	Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. <i>PLoS ONE</i> , 2012 , 7, e49513	3.7	25

298	Distinct perturbation of the translome by the antidiabetic drug metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 8977-82	11.5	149
297	Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. <i>International Journal of Cancer</i> , 2012 , 131, E105-13	7.5	40
296	Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. <i>Endocrine-Related Cancer</i> , 2012 , 19, 557-74	5.7	9
295	A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. <i>Cancer Causes and Control</i> , 2012 , 23, 959-65	2.8	29
294	The insulin and insulin-like growth factor receptor family in neoplasia: an update. <i>Nature Reviews Cancer</i> , 2012 , 12, 159-69	31.3	791
293	Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 810-20	4	32
292	Metformin and hepatic carcinogenesis. <i>Cancer Prevention Research</i> , 2012 , 5, 500-2	3.2	8
291	Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. <i>Journal of Applied Physiology</i> , 2012 , 113, 263-72	3.7	83
290	A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. <i>Clinical Cancer Research</i> , 2012 , 18, 3407-13	12.9	41
289	Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. <i>European Journal of Clinical Nutrition</i> , 2012 , 66, 1146-52	5.2	35
288	Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1970-6	5.6	20
287	The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. <i>BMJ, The</i> , 2012 , 344, e3645	5.9	202
286	A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. <i>Oncogene</i> , 2012 , 31, 1334-40	9.2	14
285	Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. <i>British Journal of Cancer</i> , 2012 , 106, 1335-41	8.7	16
284	The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. <i>Clinical Cancer Research</i> , 2012 , 18, 40-50	12.9	84
283	Reply to P. Ameri et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1396-1396	2.2	
282	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. <i>Advances in Urology</i> , 2012 , 2012, 248607	1.6	15
281	Metformin and pancreatic cancer: a clue requiring investigation. <i>Clinical Cancer Research</i> , 2012 , 18, 2723-2729	5.9	30

280	Abstract CT-04: A phase II study of neoadjuvant metformin in prostatic carcinoma 2012 ,		2
279	Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 538-538	2.2	
278	Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 561-561	2.2	
277	A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15118-e15118	2.2	
276	Dual effects of metformin on breast cancer proliferation in a randomized trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 519-519	2.2	
275	Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 414, 694-9	3.4	69
274	Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer. <i>PLoS ONE</i> , 2011 , 6, e28520	3.7	31
273	Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. <i>Oncogene</i> , 2011 , 30, 1174-82	9.2	145
272	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. <i>British Journal of Cancer</i> , 2011 , 104, 68-74	8.7	73
271	Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. <i>Gynecologic Oncology</i> , 2011 , 121, 492-8	4.9	97
270	Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. <i>American Journal of Epidemiology</i> , 2011 , 174, 642-51	3.8	53
269	Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. <i>Cancer Causes and Control</i> , 2011 , 22, 1587-95	2.8	15
268	A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. <i>Cancer Causes and Control</i> , 2011 , 22, 1627-37	2.8	39
267	Long-term effects of insulin glargine on the risk of breast cancer. <i>Diabetologia</i> , 2011 , 54, 2254-62	10.3	85
266	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. <i>Prostate</i> , 2011 , 71, 525-37	4.2	17
265	Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. <i>Cancer</i> , 2011 , 117, 1812-86.4		49
264	Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. <i>International Journal of Cancer</i> , 2011 , 128, 660-7	7.5	28
263	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. <i>Human Molecular Genetics</i> , 2011 , 20, 1241-51	5.6	60

262	Metformin and the incidence of prostate cancer in patients with type 2 diabetes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 337-44	4	110
261	Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2618-27	4	44
260	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1809-22	16.6	133
259	Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3605-10	2.2	51
258	Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 359-69	4	18
257	Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. <i>Clinical Cancer Research</i> , 2011 , 17, 5765-73	12.9	110
256	Metformin abolishes increased tumor (18)F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. <i>Cell Cycle</i> , 2011 , 10, 2770-8	4.7	33
255	ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. <i>Cancer Research</i> , 2011 , 71, 1060-70	10.1	55
254	Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3869-76	2.2	70
253	Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1599-606	2.2	71
252	IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. <i>Endocrine-Related Cancer</i> , 2011 , 18, 699-709	5.7	28
251	Insulin increases de novo steroidogenesis in prostate cancer cells. <i>Cancer Research</i> , 2011 , 71, 5754-64	10.1	80
250	Reply: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. <i>British Journal of Cancer</i> , 2011 , 105, 1467-1467	8.7	1
249	Binding between insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 is not influenced by glucose or 2-deoxy-D-glucose. <i>Journal of Biological Chemistry</i> , 2011 , 286, 16567-73	5.4	9
248	Metformin Abolishes Increased Tumor FDG Uptake Associated With a High-Energy Diet. <i>FASEB Journal</i> , 2011 , 25, lb314	0.9	
247	Low vs. high glycemic load diets reduce insulin-like growth factors and inflammatory factors in overweight persons in a controlled feeding study. <i>FASEB Journal</i> , 2011 , 25, 94.7	0.9	
246	Binding between IGF-1 and IGFBP-3 is not influenced by glucose or 2-DG. <i>FASEB Journal</i> , 2011 , 25, lb135	0.9	
245	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Cell Biology</i> , 2011 , 194, i8-i8	7.3	

244	Insulin analogues and cancer risk: cause for concern or cause of concern? <i>International Journal of Clinical Practice</i> , 2010 , 64, 628-36	2.9	37
243	Insulin-like growth factors and risk of kidney cancer in men. <i>British Journal of Cancer</i> , 2010 , 103, 132-5	8.7	22
242	Insulin-like growth factors and liver cancer risk in male smokers. <i>British Journal of Cancer</i> , 2010 , 103, 1089-92	8.7	9
241	Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 484-91	4	13
240	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 14134-9	11.5	370
239	Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2010 , 3, 279-89	3.2	32
238	Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. <i>Human Molecular Genetics</i> , 2010 , 19, 3873-84	5.6	39
237	Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2298-306	4	60
236	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. <i>Human Molecular Genetics</i> , 2010 , 19, 3089-101	5.6	46
235	Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. <i>Prostate Cancer and Prostatic Diseases</i> , 2010 , 13, 350-5	6.2	36
234	Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. <i>Endocrine-Related Cancer</i> , 2010 , 17, 351-60	5.7	178
233	Diabetes and cancer: a consensus report. <i>Diabetes Care</i> , 2010 , 33, 1674-85	14.6	1251
232	Fasting plasma insulin, C-peptide and cognitive change in older men without diabetes: results from the Physicians' Health Study II. <i>Neuroepidemiology</i> , 2010 , 34, 200-7	5.4	19
231	IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. <i>Growth Factors</i> , 2010 , 28, 243-55	1.6	39
230	Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model. <i>Journal of Urology</i> , 2010 , 183, 1619-24	2.5	13
229	Metformin and other biguanides in oncology: advancing the research agenda. <i>Cancer Prevention Research</i> , 2010 , 3, 1060-5	3.2	183
228	Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. <i>Cancer Letters</i> , 2010 , 289, 246-53	8.9	24
227	Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 537-42	3.4	35

226	Beyond steroid hormones: the new cancer endocrinology. <i>Lancet Oncology, The</i> , 2010 , 11, 501-2	21.7	
225	Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. <i>Cancer Research</i> , 2010 , 70, 8770-81	10.1	56
224	Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. <i>Diabetologia</i> , 2010 , 53, 2086-8	10.3	32
223	Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. <i>Hormones and Cancer</i> , 2010 , 1, 100-11	5	14
222	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 647-59	4.4	32
221	Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 271-9	4.4	159
220	Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. <i>Cancer Causes and Control</i> , 2010 , 21, 1-10	2.8	53
219	Diabetes and cancer: a consensus report. <i>Ca-A Cancer Journal for Clinicians</i> , 2010 , 60, 207-21	220.7	593
218	Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. <i>International Journal of Cancer</i> , 2010 , 126, 180-90	7.5	40
217	A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. <i>Prostate</i> , 2010 , 70, 848-55	4.2	122
216	Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort. <i>Prostate</i> , 2010 , 70, 906-152	15.2	33
215	Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. <i>Prostate</i> , 2010 , 70, 1628-35	4.2	19
214	Insights into the pharmacologic inhibition of insulin receptor tyrosine kinase in cancer: avoiding severe metabolic toxicity. <i>FASEB Journal</i> , 2010 , 24, lb442	0.9	
213	The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. <i>Cancer Prevention Research</i> , 2009 , 2, 557-65	3.2	79
212	Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. <i>Cancer Research</i> , 2009 , 69, 2443-52	10.1	91
211	Insulin-like growth factors and leukocyte telomere length: the cardiovascular health study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2009 , 64, 1103-6	6.4	22
210	Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 1484-91	4	38
209	Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 176-85	2.2	183

208	Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care?. <i>Cancer Prevention Research</i> , 2009 , 2, 698-701	3.2	5
207	Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects. <i>Mechanisms of Ageing and Development</i> , 2009 , 130, 771-6	5.6	48
206	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. <i>Gynecologic Oncology</i> , 2009 , 115, 193-8	4.9	24
205	A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. <i>International Journal of Geriatric Psychiatry</i> , 2009 , 24, 177-82	3.9	15
204	Insulin receptor expression by human prostate cancers. <i>Prostate</i> , 2009 , 69, 33-40	4.2	165
203	Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. <i>Oncogene</i> , 2009 , 28, 3009-21	9.2	233
202	Ageing, IGF-1, and diet. <i>Aging Cell</i> , 2009 , 8, 214; author reply 215	9.9	1
201	Do cancer cells care if their host is hungry?. <i>Cell Metabolism</i> , 2009 , 9, 401-3	24.6	32
200	Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009 , 89, 634-40	7	190
199	Current status and challenges associated with targeting mTOR for cancer therapy. <i>BioDrugs</i> , 2009 , 23, 77-91	7.9	42
198	Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1397-403	8.9	54
197	Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. <i>Current Drug Targets</i> , 2009 , 10, 923-36	3	52
196	Energy metabolism, cancer risk, and cancer prevention. <i>Recent Results in Cancer Research</i> , 2009 , 181, 51-4	1.5	8
195	Insulin and insulin-like growth factor signalling in neoplasia. <i>Nature Reviews Cancer</i> , 2008 , 8, 915-28	31.3	1532
194	Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults. <i>Journal of the American Geriatrics Society</i> , 2008 , 56, 652-60	5.6	45
193	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008 , 110, 246-50	4.9	223
192	Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. <i>Psychoneuroendocrinology</i> , 2008 , 33, 455-61	5	19
191	Insulin, insulin-like growth factors and neoplasia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 625-38	6.5	72

190	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. <i>Breast Cancer Research</i> , 2008 , 10, R86	8.3	90
189	Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. <i>Breast Cancer Research</i> , 2008 , 10, R42	8.3	12
188	High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. <i>American Heart Journal</i> , 2008 , 155, 1006-12	4.9	27
187	Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. <i>Growth Hormone and IGF Research</i> , 2008 , 18, 166-73	2	53
186	Targeting insulin and insulin-like growth factor signalling in oncology. <i>Current Opinion in Pharmacology</i> , 2008 , 8, 384-92	5.1	85
185	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. <i>Lancet Oncology</i> , 2008 , 9, 1039-47	21.7	337
184	Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. <i>Cancer Research</i> , 2008 , 68, 10238-46	10.1	320
183	Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. <i>American Journal of Epidemiology</i> , 2008 , 168, 1047-55	3.8	61
182	The type 1 insulin-like growth factor receptor pathway. <i>Clinical Cancer Research</i> , 2008 , 14, 6364-70	12.9	342
181	The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. <i>Cancer Prevention Research</i> , 2008 , 1, 369-75	3.2	233
180	Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. <i>Endocrine-Related Cancer</i> , 2008 , 15, 833-9	5.7	150
179	Vitamin D pathway polymorphisms in relation to mammographic breast density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2505-8	4	5
178	IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: no association with incident colorectal cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 1832-4	4	13
177	Fasting insulin levels and cognitive decline in older women without diabetes. <i>Neuroepidemiology</i> , 2008 , 30, 174-9	5.4	35
176	Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 880-8	4	49
175	Plasma insulinlike growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. <i>Clinical Chemistry</i> , 2008 , 54, 1682-8	5.5	18
174	Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6944-54	12.9	65
173	A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 921-9	4	199

172	Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. <i>Clinical Cancer Research</i> , 2008 , 14, 8263-9	12.9	50
171	Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 252-4	4	20
170	Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3196-203	2.2	139
169	IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). <i>PLoS ONE</i> , 2008 , 3, e2578	3.7	93
168	Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. <i>Annals of Internal Medicine</i> , 2008 , 149, 461-71, W83-8	8	226
167	Insulin-Like Growth Factors and Neoplasia. <i>Novartis Foundation Symposium</i> , 2008 , 84-107		39
166	Hormonal profile of diabetic men and the potential link to prostate cancer. <i>Cancer Causes and Control</i> , 2008 , 19, 703-10	2.8	44
165	Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. <i>Prostate</i> , 2008 , 68, 1477-86	4.2	48
164	IGF Signaling Is Critical for Growth and Survival of T-Cell Acute Lymphoblastic Leukemia Cells and Is Potentiated by Notch Upregulation of IGF1R. <i>Blood</i> , 2008 , 112, 3811-3811	2.2	0
163	Milk consumption and the prepubertal somatotrophic axis. <i>Nutrition Journal</i> , 2007 , 6, 28	4.3	83
162	Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. <i>Prostate</i> , 2007 , 67, 1354-61	4.2	45
161	Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. <i>Oncogene</i> , 2007 , 26, 1811-9	9.2	80
160	Prediagnostic C-peptide and risk of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 2164-5	4	17
159	Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. <i>Cancer Research</i> , 2007 , 67, 11083-91	10.1	64
158	Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. <i>Carcinogenesis</i> , 2007 , 28, 2567-74	4.6	62
157	Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. <i>British Journal of Cancer</i> , 2007 , 97, 98-104	8.7	51
156	Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 716-22	4	21
155	Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1793-800	9.7	145

154	C-reactive protein concentrations and subsequent ovarian cancer risk. <i>Obstetrics and Gynecology</i> , 2007 , 109, 933-41	4.9	70
153	Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1319-25	5.6	94
152	Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. <i>Clinical Cancer Research</i> , 2007 , 13, 3611-6	12.9	171
151	Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 2101-9	4	77
150	Body shape throughout life and correlations with IGFs and GH. <i>Endocrine-Related Cancer</i> , 2007 , 14, 721-32	3.7	58
149	Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 929-33	4	47
148	Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. <i>Cancer Research</i> , 2007 , 67, 10804-12	10.1	747
147	Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 1691-5	4	31
146	Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. <i>Cancer Research</i> , 2007 , 67, 7923-8	10.1	58
145	Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 161-4	4	62
144	Glioma risk in relation to serum levels of insulin-like growth factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 844-6	4	22
143	Insulin, insulin-like growth factors, insulin resistance, and neoplasia. <i>American Journal of Clinical Nutrition</i> , 2007 , 86, s820-2	7	57
142	Plasma IGF-I levels and cognitive performance in older women. <i>Neurobiology of Aging</i> , 2007 , 28, 135-42	5.6	51
141	The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. <i>Cancer Letters</i> , 2007 , 255, 300-6	9.9	26
140	Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. <i>Breast Cancer Research</i> , 2007 , 9, R18	8.3	59
139	Insulin-like growth factor-related signaling and cancer development. <i>Recent Results in Cancer Research</i> , 2007 , 174, 49-53	1.5	46
138	Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 100, 389-96	4.9	60
137	Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006 , 118, 1279-84	7.5	27

136	Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. <i>International Journal of Cancer</i> , 2006 , 118, 2105-9	7.5	113
135	Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. <i>Endocrine-Related Cancer</i> , 2006 , 13, 583-92	5.7	114
134	Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. <i>Cancer Research</i> , 2006 , 66, 588-97	10.1	50
133	Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1977-83	4	266
132	C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 750-5	4	64
131	Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 972-8	4	111
130	No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 2010-2	4	15
129	Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. <i>Molecular Pharmacology</i> , 2006 , 70, 1534-41	4.3	64
128	Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. <i>Cancer Research</i> , 2006 , 66, 10269-73	10.1	873
127	Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). <i>Growth Hormone and IGF Research</i> , 2006 , 16, 86-92	2	20
126	Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. <i>American Journal of Clinical Nutrition</i> , 2006 , 84, 1518-26	7	18
125	PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 336, 1056-61	3.4	45
124	Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. <i>Breast Cancer Research</i> , 2005 , 7, R796-807	8.3	78
123	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. <i>Breast Cancer Research</i> , 2005 , 7, R570-9	8.3	94
122	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. <i>Oncogene</i> , 2005 , 24, 4736-40	9.2	53
121	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. <i>Oncogene</i> , 2005 , 24, 4281-92	9.2	225
120	Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. <i>Cancer Causes and Control</i> , 2005 , 16, 255-62	2.8	61
119	Individualizing interventions for cancer prevention. <i>Recent Results in Cancer Research</i> , 2005 , 166, 63-9	1.5	

118	Levels of C-peptide and mammographic breast density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 2661-4	4	13
117	Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 2673-80	4	25
116	A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 850-5	4	187
115	Racial differences in premenopausal endogenous hormones. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 2147-53	4	85
114	Vitamin D and calcium intakes from food or supplements and mammographic breast density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1653-9	4	78
113	Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1402-10	4	16
112	Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 455-60	2.2	170
111	Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1270-3	4	25
110	Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 699-704	4	132
109	Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1065-73	4	125
108	Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 864-71	2.2	37
107	A prospective study of plasma C-peptide and colorectal cancer risk in men. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 546-53	9.7	268
106	Insulin-like growth factors and neoplasia. <i>Nature Reviews Cancer</i> , 2004 , 4, 505-18	31.3	1286
105	Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. <i>British Journal of Cancer</i> , 2004 , 90, 1825-9	8.7	40
104	Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. <i>International Journal of Cancer</i> , 2004 , 108, 334-41	7.5	170
103	Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. <i>International Journal of Cancer</i> , 2004 , 108, 773-9	7.5	77
102	Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 313, 709-15	3.4	27
101	Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 316, 421-8	3.4	27

100	Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 438-44	4	21
99	A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 573-82	4	22
98	Insulin-like growth factors and neoplasia. <i>Novartis Foundation Symposium</i> , 2004 , 262, 84-98; discussion 98-107, 265-8		36
97	Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. <i>International Journal of Cancer</i> , 2003 , 107, 60-4	7.5	71
96	Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. <i>BJU International</i> , 2003 , 92, 699-702	5.6	13
95	Challenges to cancer control by screening. <i>Nature Reviews Cancer</i> , 2003 , 3, 297-303	31.3	26
94	Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. <i>American Journal of Epidemiology</i> , 2003 , 158, 424-31	3.8	43
93	Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 917; author reply 918-9	9.7	
92	Soy isoflavones in the treatment of prostate cancer. <i>Nutrition and Cancer</i> , 2003 , 47, 111-7	2.8	127
91	Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. <i>Journal of Clinical Investigation</i> , 2003 , 112, 1429-1436	15.9	132
90	Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003 , 12, 84-9	4	109
89	Association of markers of insulin and glucose control with subsequent colorectal cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003 , 12, 412-8	4	73
88	Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. <i>Cancer Research</i> , 2003 , 63, 3991-4	10.1	78
87	Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003 , 12, 1429-37	4	29
86	Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. <i>Journal of Surgical Oncology</i> , 2002 , 81, 75-9	2.8	20
85	A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. <i>International Journal of Cancer</i> , 2002 , 100, 332-6	7.5	80
84	Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1099-106	9.7	325
83	Lycopene in the treatment of prostate cancer. <i>Pure and Applied Chemistry</i> , 2002 , 74, 1443-1450	2.1	20

82	Effects of lycopene supplementation in patients with localized prostate cancer. <i>Experimental Biology and Medicine</i> , 2002 , 227, 881-5	3.7	132
81	Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 for Prostate Cancer Detection in Patients Undergoing Prostate Biopsy. <i>Journal of Urology</i> , 2002 , 168, 2426-2430	2.5	21
80	Risk of cancer after growth-hormone treatment. <i>Lancet, The</i> , 2002 , 360, 268-9	4.0	17
79	Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002 , 11, 852-61	4	120
78	Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002 , 11, 862-7	4	54
77	Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002 , 11, 1413-8	4	31
76	Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. <i>Cancer Research</i> , 2002 , 62, 7372-6	10.1	26
75	Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. <i>Medical Science Monitor</i> , 2002 , 8, BR521-6	3.2	64
74	Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. <i>British Journal of Cancer</i> , 2001 , 85, 428-30	8.7	106
73	Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1852-7	9.7	725
72	Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1330-6	9.7	144
71	Tissue-specific targeting of the pthrp gene: the generation of mice with floxed alleles. <i>Endocrinology</i> , 2001 , 142, 2070-7	4.8	30
70	Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1274-80	5.6	171
69	Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. <i>Journal of the Neurological Sciences</i> , 2001 , 182, 107-13 ²	3.2	15
68	Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. <i>Molecular Genetics and Metabolism</i> , 2001 , 72, 144-54	3.7	94
67	Other novel agents: Rationale and current status as chemopreventive agents. <i>Urology</i> , 2001 , 57, 86-9	1.6	13
66	Insulin-like growth factors and prostate cancer. <i>Epidemiologic Reviews</i> , 2001 , 23, 59-66	4.1	73
65	Novel Promoter Polymorphism in Insulin-Like Growth Factor-Binding Protein-3: Correlation with Serum Levels and Interaction with Known Regulators. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1274-1280	5.6	137

64	H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. <i>FEBS Journal</i> , 2000 , 267, 4020-7		44
63	Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. <i>Annals of Oncology</i> , 2000 , 11, 307-13	10.3	73
62	Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3758-67	2.2	863
61	Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. <i>Journal of the American Academy of Dermatology</i> , 2000 , 42, 1003-1007	4.5	20
60	The question of a link between insulin-like growth factor physiology and neoplasia. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl B, S21-4	2	11
59	First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia. <i>Growth Hormone and IGF Research</i> , 2000 , 10, S1-S3	2	8
58	Insulin-like growth factor physiology and neoplasia. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl A, S6-7	2	20
57	Insulin-like growth factors and mammographic density. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl A, S24-5	2	11
56	A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl A, S28-9	2	42
55	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl A, S30-1	2	37
54	Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. <i>Growth Hormone and IGF Research</i> , 2000 , 10 Suppl A, S32-3	2	31
53	Insulin-like growth factor physiology and cancer risk. <i>European Journal of Cancer</i> , 2000 , 36, 1224-8	7.5	248
52	Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 620-5	9.7	916
51	Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. <i>Molecular and Cellular Biochemistry</i> , 1999 , 199, 41-8	4.2	16
50	A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. <i>Cancer</i> , 1999 , 85, 1284-92	6.4	49
49	Circulating IGF-I: New Perspectives for a New Century. <i>Trends in Endocrinology and Metabolism</i> , 1999 , 10, 136-141	8.8	112
48	Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. <i>Urology</i> , 1999 , 54, 1120-5	1.6	34
47	Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. <i>Breast Cancer Research and Treatment</i> , 1998 , 47, 209-17	4.4	91

46	Insulin-like growth factors and prostate cancer. <i>Cancer and Metastasis Reviews</i> , 1998 , 17, 383-90	9.6	117
45	Cancer controversy. <i>Nature</i> , 1998 , 392, 752	50.4	1
44	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. <i>Journal of Surgical Oncology</i> , 1998 , 69, 21-7	2.8	83
43	Insulin-like growth factor-I and risk of breast cancer. <i>Lancet, The</i> , 1998 , 352, 489	40	3
42	Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. <i>Lancet, The</i> , 1998 , 351, 1393-6	40	1556
41	I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus. <i>European Journal of Cancer</i> , 1998 , 34, S11-S12	7.5	0
40	Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. <i>Science</i> , 1998 , 279, 563-63.3	63.3	1703
39	Mechanisms of antineoplastic action of somatostatin analogs. <i>Experimental Biology and Medicine</i> , 1998 , 217, 143-52	3.7	122
38	Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. <i>Endocrinology</i> , 1998 , 139, 807-10	4.8	104
37	IGF-I physiology and breast cancer. <i>Recent Results in Cancer Research</i> , 1998 , 152, 63-70	1.5	26
36	Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma 1998 , 69, 21		2
35	Overexpression of insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to insulin-like growth factors in vitro and reduced tumour growth in vivo. <i>International Journal of Oncology</i> , 1997 , 11, 193-7	1	
34	Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 652-6	9.7	83
33	Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 237, 690-3	3.4	130
32	Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. <i>Cancer</i> , 1997 , 80, 435-41	6.4	144
31	The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors. <i>Genomics</i> , 1996 , 34, 63-8	4.3	31
30	Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. <i>Digestion</i> , 1996 , 57 Suppl 1, 29-33	3.6	14
29	Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. <i>Journal of Biological Chemistry</i> , 1996 , 271, 1016-21	5.4	156

28	Enhancement of the Antineoplastic Effects of Tamoxifen by Somatostatin Analogues 1996 , 359-368		
27	HH2A, an immortalized bovine mammary epithelial cell line, expresses the gene encoding mammary derived growth inhibitor (MDGI). <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1995 , 31, 25-9	2.6	21
26	Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. <i>Progress in Growth Factor Research</i> , 1995 , 6, 495-501		8
25	Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. <i>Cancer</i> , 1995 , 75, 23-8	6.4	54
24	Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. <i>Journal of the National Cancer Institute</i> , 1994 , 86, 628-32	9.7	11
23	Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 198, 292-7	3.4	60
22	Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 203, 253-9	3.4	46
21	In-vitro fertilisation and family history of breast cancer. <i>Lancet, The</i> , 1994 , 344, 610-1	4.0	10
20	The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer. <i>Genomics</i> , 1993 , 18, 414-7	4.3	16
19	Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. <i>European Journal of Cancer</i> , 1993 , 29A, 1368-72	7.5	41
18	Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. <i>European Journal of Cancer</i> , 1992 , 28A, 788-93	7.5	31
17	Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. <i>Metabolism: Clinical and Experimental</i> , 1992 , 41, 119-20	12.7	3
16	Tamoxifen reduces serum insulin-like growth factor I (IGF-I). <i>Breast Cancer Research and Treatment</i> , 1992 , 22, 91-100	4.4	90
15	Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. <i>Medical and Pediatric Oncology</i> , 1991 , 19, 283-8		8
14	A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. <i>Cancer Investigation</i> , 1991 , 9, 513-20	2.1	3
13	Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 457-60	3.5	10
12	Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. <i>Journal of the National Cancer Institute</i> , 1990 , 82, 301-5	9.7	88
11	Combination chemotherapy with carboplatin and bleomycin for advanced and recurrent head and neck cancer: a phase II study. <i>Journal of Surgical Oncology</i> , 1988 , 39, 215-6	2.8	2

10	Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 1988 , 154, 326-31	3-4	66
9	Presence of somatomedin receptors on primary human breast and colon carcinomas. <i>Cancer Letters</i> , 1987 , 38, 223-30	9-9	115
8	MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. <i>Biochemical and Biophysical Research Communications</i> , 1985 , 128, 898-905	3-4	280
7	Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. <i>Biochemical and Biophysical Research Communications</i> , 1985 , 131, 207-15	3-4	71
6	Computer-aided information management systems in clinical trials. A physician's perspective. <i>Computer Programs in Biomedicine</i> , 1983 , 16, 243-51		8
5	The insulin/insulin-like growth-factor receptor family as a therapeutic target in oncology	110-118	
4	Tissue-Specific Targeting of the Pthrp Gene: The Generation of Mice with Floxed Alleles		9
3	Translational and HIF1-Dependent Metabolic Reprogramming Underpin Oncometabolome Plasticity and Synergy Between Oncogenic Kinase Inhibitors and Biguanides. <i>SSRN Electronic Journal</i> ,	1	1
2	Repression of LKB1 by miR-17~92 sensitizes MYC-dependent lymphoma to biguanide treatment		1
1	A Neanderthal OAS1 isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies		4